Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Generate Biomedicines Inc (GENB)

Generate Biomedicines Inc (GENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Thu Aug 6, 6:00AM CDT

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be...

GENB : 14.27 (-3.06%)
Generate Biomedicines: Q2 Earnings Snapshot AP - Thu Aug 6, 5:21AM CDT

Generate Biomedicines: Q2 Earnings Snapshot

GENB : 14.27 (-3.06%)
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts PR Newswire - Mon Jun 22, 7:00AM CDT

Newly Constructed Phase 2 now 100% Leased

GENB : 14.27 (-3.06%)
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire - Thu May 28, 3:20PM CDT

SOMERVILLE, Mass. , May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday,...

GENB : 14.27 (-3.06%)
Businessman touching the brain working of Artificial Intelligence (AI) Automation by Suttiphong Chandaeng via Shutterstock
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment Barchart - Wed May 20, 2:45PM CDT

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

NVDA : 217.50 (-0.02%)
GENB : 14.27 (-3.06%)
NVS : 154.61 (-1.39%)
AMGN : 414.30 (-0.70%)
MarketBeat.com
A Deep Dive Into NVIDIA’s Latest Portfolio Moves MarketBeat - Tue May 19, 1:05PM CDT

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

NVDA : 217.50 (-0.02%)
CRWV : 90.32 (+2.42%)
GENB : 14.27 (-3.06%)
INTC : 97.71 (+0.19%)
SNPS : 410.91 (-0.19%)
COHR : 328.57 (+1.05%)
NBIS : 193.23 (+4.95%)
RXRX : 3.35 (+1.82%)
NOK : 9.44 (+3.40%)
LITE : 820.59 (+0.87%)
MRVL : 212.31 (+1.80%)
Generate Biomedicines: Q1 Earnings Snapshot AP - Thu May 7, 5:24AM CDT

Generate Biomedicines: Q1 Earnings Snapshot

GENB : 14.27 (-3.06%)
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire - Thu May 7, 5:16AM CDT

SOMERVILLE, Mass. , May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted...

GENB : 14.27 (-3.06%)
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering PR Newswire - Thu Feb 26, 6:58PM CST

SOMERVILLE, Mass. , Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology...

GENB : 14.27 (-3.06%)

Barchart Exclusives

This Mag 7 Dividend Stock Is Trading Near 2026 Highs. Why It's Still a Buy. Barchart - Tue Aug 11, 6:30PM CDT
Microsoft's dividend yield is the highest among the Magnificent 7 companies. Reasonable valuations and strong momentum in AI monetization make MSFT stock a buy despite the sharp rally from its 2026 lows. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.